Antioxidants (Dec 2022)

<i>Actaea racemosa</i> L. Rhizome Protect against MPTP-Induced Neurotoxicity in Mice by Modulating Oxidative Stress and Neuroinflammation

  • Marika Cordaro,
  • Ramona D’Amico,
  • Roberta Fusco,
  • Tiziana Genovese,
  • Alessio Filippo Peritore,
  • Enrico Gugliandolo,
  • Rosalia Crupi,
  • Davide Di Paola,
  • Livia Interdonato,
  • Daniela Impellizzeri,
  • Salvatore Cuzzocrea,
  • Rosanna Di Paola,
  • Rosalba Siracusa

DOI
https://doi.org/10.3390/antiox12010040
Journal volume & issue
Vol. 12, no. 1
p. 40

Abstract

Read online

Parkinson’s disease (PD) is a dopaminergic neuron-related neurodegenerative illness. Treatments exist that alleviate symptoms but have a variety of negative effects. Recent research has revealed that oxidative stress, along with neuroinflammation, is a major factor in the course of this disease. Therefore, the aim of our study was to observe for the first time the effects of a natural compound such as Actaea racemosa L. rhizome in an in vivo model of PD induced by neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). For the study, mice received four injections of MPTP (20 mg/kg) for the induction of PD. Starting 24 h after the first administration of MPTP we treated mice with Actaea racemosa L. rhizome (100 mg/kg) daily for seven days. Our findings clearly demonstrated that Actaea racemosa L. rhizome treatment decreases oxidative stress by activating redox balance enzymes such as Nrf2/HO-1. We also demonstrated that Actaea racemosa L. rhizome is capable of modulating inflammatory indicators involved in PD, such as IκB-α, NF-κB, GFAP and Iba1, thus reducing the degeneration of dopaminergic neurons and motor and non-motor alterations. To summarize, Actaea racemosa L. rhizome, which is subject to fewer regulations than traditional medications, could be used as a dietary supplement to improve patients’ brain health and could be a promising nutraceutical choice to slow the course and symptoms of PD.

Keywords